OTS---Trading remains range-bound as the company announces its financial results for the fiscal year ending March 2026.

Range-bound trading. On the 8th, after the close of trading, the company announced its financial results for the fiscal year ending March 2026. Revenue increased to 8.08 billion yen (a 7.8% increase from the previous term) due to income from analysis services and other sources. However, operating losses were incurred primarily due to the recording of R&D expenses from the continued implementation of fundamental research and drug discovery research on pharmaceutical candidate substances, costs associated with clinical development progress in three areas—low-molecular-weight drugs, cancer peptide vaccines, and antibody drugs—as well as the recording of cost of goods sold related to the precision oncology medical business.

Fisco JapanMay 10 21:31 ET

OTS Forecasts Swing to Loss in Fiscal H1

MT NewswiresFeb 4 06:15 ET

OTS Holdings: Financial Statements and Related Announcement-Profit Guidance

SGXFeb 4 04:25 ET · Announcements

OTS Holdings Limited Conducts Annual General Meeting

TipRanksNov 20, 2025 04:42 ET

OTS Holdings Limited Faces Revenue Challenges Amidst Market Competition

TipRanksOct 17, 2025 08:44 ET

OTS Holdings Limited Announces Change of Company Secretary

TipRanksSep 1, 2025 07:12 ET